A family of interferon (IFN) regulatory factors (IRFs) The virus-induced expression of interferon (IFN) genes in infected cells involves interplay of several constitutively expressed and virus-activated transcriptional factors (1). Two of these factors binding to the virus-inducible element of the IFN-3 gene have been proposed to play a crucial role in the regulation of expression of IFN-a and IFN-,3 genes. Interferon regulatory factor 1 (IRF-1) was shown to act as an activator, and the closely related IRF-2 was a repressor (2). It was proposed that induction of the IFN-,3 gene was the result of the removal of repressor IRF-2 and the subsequent binding of the activator IRF-1 (3). Several observations supported this model. Expression of IRF-1 was found to be upregulated in virus-infected cells. The IRF-1 binding sites were identified in the IFN-3 gene promoter region and reporter plasmids with multiple repeats of the AAGTGA hexanucleotides (which are the strong IRF-1 binding site) were inducible by overexpression of IRF-1. This transactivation could be repressed by (2). In embryonal carcinoma cells, overexpression of IRF-1 induced both the transfected and the endogenous IFN-a and -,B genes (4). Moreover, a decrease in IFN-,B induction was observed in cells expressing the IRF-1 antisense mRNA (5).
The virus-induced expression of interferon (IFN) genes in infected cells involves interplay of several constitutively expressed and virus-activated transcriptional factors (1) . Two of these factors binding to the virus-inducible element of the IFN-3 gene have been proposed to play a crucial role in the regulation of expression of IFN-a and IFN-,3 genes. Interferon regulatory factor 1 (IRF-1) was shown to act as an activator, and the closely related IRF-2 was a repressor (2) . It was proposed that induction of the IFN-,3 gene was the result of the removal of repressor IRF-2 and the subsequent binding of the activator IRF-1 (3) . Several observations supported this model. Expression of IRF-1 was found to be upregulated in virus-infected cells. The IRF-1 binding sites were identified in the IFN-3 gene promoter region and reporter plasmids with multiple repeats of the AAGTGA hexanucleotides (which are the strong IRF-1 binding site) were inducible by overexpression of IRF-1. This transactivation could be repressed by IRF-2 (2) . In embryonal carcinoma cells, overexpression of IRF-1 induced both the transfected and the endogenous IFN-a and -,B genes (4) . Moreover, a decrease in IFN-,B induction was observed in cells expressing the IRF-1 antisense mRNA (5) .
In contrast, studies of IFN-a promoters did not support the role of IRF-1 as the limiting factor in the virus-mediated induction of these genes. In mouse cells, overexpression of
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IRF-1 was sufficient to induce transcription from the IFN-a promoters: however, it induced expression of both virusinducible and -uninducible IFN-a promoters (6) . Further, the binding of IRF-1 to the respective IRF-1 binding sites in murine and human IFN-a promoters was very weak, suggesting that if IRF-1 plays a role in induction of IFN-a genes, it cooperates with another binding protein(s) (7) . The strongest argument against the limiting role of IRF-1 and IRF-2 is that the virus-mediated induction of IFN-a or -3 genes was not altered in IRF-1 null mice or in cells with the IRF-1 gene deleted (8, 9) , suggesting that IRF-1 function can be replaced by other transactivators, which may bind to the same domain.
IRF-1 was also shown to bind to the interferon-stimulated response element (ISRE) present in promoters of genes activated by IFN (10) and to have a direct role in regulation of expression of several IFN-induced genes (11) (12) (13) (16) . The ISGF3'y (p48) present in the cytoplasm is assembled, in cells treated with IFN-a, together with the Statl and Stat2 proteins into the ISGF3 complex and mediates binding of this complex to the ISRE (14, 17) . c-Myb also belongs to the family of IRF-1-like proteins, although its relationship to the IFN system is unclear (14) . lThe sequence reported in this paper has been deposited in the GenBank database (accession no. Z56281).
was screened for homology by using the BLAST network service provided by the National Center for Biotechnology Information. Several overlapping ESTs showing homology to IRF-1 and IRF-2 were identified, and one that appeared to be full-length was sequenced and designated IRF-3. The first designated methionine codon in the IRF-3 clone is likely to be the start codon because its context (ACC-AUG-G) fits the Kozak consensus sequence for translation (RCC-AUG-G). The IRF-3 clone was used for subsequent studies.
Plasmid Constructs. The IRF-3 expression plasmid was prepared by cloning the BamHI-Xho I fragment containing the IRF-3 cDNA from the pSKIRF-3 plasmid behind the cytomegalovirus promoter in the pCDNAINEO vector (Invitrogen). The IRF-1 expression plasmid has been described (18) . The Gal4-IRF fusion plasmids were constructed by first amplifying full-length IRF-1, IRF-2, and IRF-3 cDNAs by PCR. After digestion of the amplified fragments with Xho I andXba I (for IRF-1 and IRF-3) or Sal I andXba I (for IRF-2), these fragments were cloned in-frame with the GAL4 sequence corresponding to aa 1-147 of the Gal4 DNA binding domain in pSG424 (19) . The indicator plasmids containing the chloramphenicol acetyltransferase (CAT) gene inserted behind the virus-inducible 452-nt IFNA4 promoter region (IFNA4/CAT) or the IFN-inducible promoter of ISG15 (ISG15/CAT) or three copies of ISRE (from ISG15) inserted in front of the -119 human immunodeficiency virus promoter-CAT plasmid have been described (7) . For construction of glutathione S-transferase (GST)-IRF and GST-ISGF3,y fusion plasmids, the EcoRI-Xho I fragment of the IRF-3 cDNA or the PCRamplified ISGF3,y cDNA were cloned into pGEX-4T-2 vector (Pharmacia Biotech) digested with the same enzymes. For construction of the GST-IRF-1 fusion plasmid, murine IRF-1 cDNA isolated as a Pst I fragment from pIRF-1AS (18) was cloned into pGEX-4T-2 digested with Sal I.
In Vitro Translation of IRF-3 mRNA and Expression of GST Fusion Protein. IRF-3 mRNA was translated in a rabbit reticulocyte lysate (Promega). The GST fusion proteins were purified from bacterial lysates by affinity chromatography on a glutathione-agarose column (Sigma). To remove the GST portion, fusion protein bound to glutathione-agarose beads was treated with thrombin (20%, wt/wt) for 2 hr and recombinant IRF-3 was eluted with phosphate-buffered saline.
Transfection and CAT Assay. Transfections were done by calcium phosphate precipitation (6, 7) . Treatment with type I IFN (100 units/ml) or infection with Newcastle disease virus (NDV) (multiplicity of infection, 5) was done 16 hr after transfection for 8 hr. IFN or virus inoculum was then removed, and cells were washed and incubated in medium for 16 hr before harvest for the CAT assay.
Gel Mobility-Shift Assay. The purified GST-IRF fusion proteins (100 ng) were incubated with labeled probes (1-10 pg) in the presence of nonspecific competitor poly(dIdC) (1 ,ug) as described (17) and the protein-DNA complexes were resolved in a nondenaturing 4% polyacrylamide gel. The following oligonucleotides were used for DNA-binding studies or as competitors: ISRE, 5'-CAGTTTCGGTTTCCCTTT-3'; positive regulatory domain I (PRD-I), 5'-GAGAAGTGAA-AGTGGGAACCCTCTCCTT-3' (the underlined sequence was used for annealing of primer 5'-AAGGAGAGGG-3' and synthesis of a complementary strand).
Southern and Northern Hybridizations and Si Nuclease Analysis. Southern hybridization used 32P-labeled IRF-3 cDNA as a probe. Tissue distribution of IRF-3 mRNA was determined with a multiple-tissue Northern blot of poly(A)+ RNA (Stratagene) probed with 32P-labeled IRF-3 cDNA by modified hybridization (20) . Total RNA isolated from NDVinfected HeLa cells was analyzed by hybridization with 32p-labeled IRF-3 cDNA probe as described (7) . For S1 nuclease analysis, total RNA was hybridized with 32P-labeled IRF-3 and ,3-actin RNA probes.
RESULTS
Identification and Characterization of the IRF-3 Clone. A database of ESTs (21) generated from multiple human tissues at Human Genome Sciences, Inc., and the Institute of Genomic Research was searched for homologs of IRF-1 and IRF-2 by using the BLAST algorithm (22) . A cDNA with an open reading frame of 427 aa was identified ( Fig. 1) , designated IRF-3, characterized, and used for further studies.
In addition to IRF-1 and IRF-2, IRF-3 is also homologous to ICSBP and ISGF3,y (Fig. 2) . The homology to IRF-1 and IRF-2 is restricted to the N-terminal 110 aa containing the characteristic tryptophan repeats, whereas the homology to ICSBP and ISGF3,y extends through the whole coding region. In addition, IRF-3, ISGF-y, and ICSBP contain an identical domain of 7 aa (positions 34-40) from which 6 aa are also preserved in IRF-1 and IRF-2. In the N-terminal region, IRF-3 is 34% and 37% identical with IRF-1 and IRF-2 respectively, whereas the values for ICSBP and ISGF3,y are 39.8% and 35.2%, respectively. In the C-terminal region, IRF-3 is 25.3% identical to ICSBP and 18.6% identical to ISGF3-y.
Expression of IRF-3 Gene in Various Tissues and Cells. Southern hybridization of human genomic DNA (HeLa cells) showed a single copy of the IRF-3 gene (Fig. 3A) . Northern hybridization detected a 1.6-kb band in all tissues examined, indicating that this gene is expressed constitutively (Fig. 3B) . To determine whether IRF-3 gene expression is further stimulated in virus-infected or IFN-treated cells, total RNA isolated from either NDV-infected or IFN-treated cells at various times postinduction was analyzed by Northern hybridization and S1 nuclease mapping. From 1 to 24 hr after infection, the relative levels of IRF-3 mRNA in NDV-infected HeLa cells did not change significantly, nor were there changes in the (Fig. 3C ). These data indicate that expression of the IRF-3 gene is not stimulated in infected or IFN-treated cells.
Identification of a 50-kDa IRF-3 Peptide and DNA-Binding Properties of IRF-3 Synthesized in Bacteria. Translation of IRF-3 mRNA in the rabbit reticulocyte system yielded a 50-kDa polypeptide (data not shown), indicating that IRF-3 is very similar in size to ISGFy (48 kDa) and IRF-1 (45 kDa) (2, 14) . IRF-3 expressed as a GST fusion protein in bacteria was purified on a glutathione-agarose beads column and used in DNA-binding assays. The GST protein alone did not bind to any of the probes used. In a mobility-shift assay, the GST-B A IRF-3 protein formed with the ISRE probe one major, fastmoving complex (Fig. 4A, lane 2) and two minor, slowly moving complexes (seen after a prolonged exposure; Fig. 4A,  lane 4) . Addition of antibodies to the GST fusion protein completely eliminated the complex formation, indicating that the multiple complexes formed represented binding of the GST-IRF-3 fusion protein and were not the result of its degradation (data not shown). Removal of GST fusion protein from IRF-3 by cleavage with thrombin did not change the binding pattern (data not shown). Complex formation was specific; it was inhibited by a 50-fold excess of nonradioactive ISRE oligonucleotide but not by a nonspecific polynucleotide (Fig. 4B) . The binding of GST-IRF-1 fusion protein to ISRE showed only one DNA-protein complex (Fig. 4A, lanes 1 and  3) , suggesting that the binding properties of IRF-1 and IRF-3 are not identical. Since IRF-1 binds very effectively to the PRD-I domain present in the IFN-,B gene promoter region, we compared the binding of these two proteins to the PRD-I probe. IRF-1 bound very strongly to this probe and formed a single DNA-protein complex (Fig. 4A, lane 5) , but no complex formation was detected between IRF-3 and PRD-I (lane 6). Thus, IRF-3 is a DNA-binding protein that can bind specifically to ISRE, but not to the IRF-1 binding site. Since ISGF3,y binds only to the ISRE, but not to PRD-I (17), we compared the binding of ISGF3,y and IRF-3 GST fusion proteins with the I "pw 0 ISRE probe. The gel mobility-shift assay showed weak binding of GST-ISGF3-y fusion protein and only one DNA-protein complex was detected (Fig. 4A, lane 7) , indicating that recombinant IRF-3 has a much stronger affinity for the ISRE than does recombinant ISGF3y.
IRF-3 Activates the ISG15 Promoter Region and Minimal Promoter Containing Multiple Copies of the ISRE in a Transient Expression Assay. To determine whether IRF-3 can activate promoters containing ISREs or promoters of IFN genes containing the virus-inducible element, the IRF-3 cDNA was placed under the control of the cytomegalovirus promoter.
Cotransfection of IRF-3 expression plasmid with a reporter plasmid containing 2000 nt of the ISG15 promoter region inserted 5' of the CAT gene resulted in a dose-dependent increase in CAT activity (Fig. 5A ). This promoter region is activated by IFN-a (17, 23, 24 ). When IFN induction was done under suboptimal conditions (8-hr treatment) leading to only a small increase in CAT activity, transfection with IRF-3, followed by 8 hr of IFN treatment, showed a highly synergistic activation (25- (6) was cotransfected with either IRF-I or IRF-3 expression plasmid (5 ,ug) and pCHI 10 (1 ,ug) . Where indicated, the transfected cells were infected with NDV. Percent chloramphenicol conversion was calculated by dividing the radioactivity (cpm) present in 3-acetylchloramphenicol and 1-acetylchloramphenicol fractions by the sum of radioactivity in unconverted chloramphenicol and these two fractions. The levels of CAT activity were normalized to the constant level of /3-galactosidase. The maximal difference in 3-galactosidase activity in a single experiment was 2-fold. An average value from three independent experiments is given. There was 15% variability between individual experiments. by IRF-3 and 3-fold increase by IFN). While treatment with IFN for 24 hr led to a significant increase in CAT activity, the synergy between IFN and IRF-3 was less obvious (20-fold increase by IFN and IRF-3 and 10-fold increase by IFN alone).
In contrast, cotransfection of IRF-3 expression plasmid with the reporter plasmid containing the IFNA4 promoter region in front of the CAT gene did not lead to increased CAT activity, indicating that the IFNA4 promoter is not activated by IRF-3 (Fig. SB) . This promoter is, however, activated by cotransfection with the IRF-1 expression plasmid or by viral infection (NDV). Although IRF-3 did not affect IRF-1-mediated stimulation (data not shown), infection of IRF-3-transfected cells led to an -3-fold increase in virus-mediated induction of the IFNA4 promoter. Thus, whereas overexpression of IRF-3 alone was unable to induce this promoter, it could enhance the NDV-mediated induction of the IFNA4 promoter.
Gal4-IRF-1, but Not Gal4-IRF-3, Fusion Protein Can Activate Transcription. To determine whether IRF-3 contains an activation region similar to that identified in IRF-1 (25), we tested the ability of IRF-3 to stimulate transcription and fused IRF-3 cDNA in-frame to the coding sequence for the DNAbinding domain of Gal4. The reporter contained five Gal4 binding sites inserted upstream of a minimal thymidine kinase promoter. Gal4-IRF-1, but not Gal4-IRF-3 or Gal4-IRF-2, stimulated the transcription of the CAT gene (Fig. 6) (28) . (iii) Although IRF-3 does not activate the IFNA4 promoter, it enhances the virus-mediated induction of that promoter. This activation may result from the association of IRF-3 with virus-modified cellular factors and a consequent increase in the IRF-3 binding to the virus-inducible element in the IFNA4 promoter. Modification of the DNA-binding domain through interaction of the DNA-binding protein with a protein unable to bind DNA was reported for the Oct-I protein, which recognized a G+A-rich binding site upon interaction with the viral protein VP16 (29, 30) .
In conclusion, our data suggest the existence of a DNAbinding protein, IRF-3, that by association with cellular proteins activated by viral infection or by IFN, increases transcriptional activity of targeted promoters. The proteins that interact with IRF-3 and the target gene that these complexes activate are unknown. Recently, a novel nuclear factor binding to the ISRE was identified in cells infected with vesicular stomatitis virus (31) . Whether this protein is IRF-3 is unknown. However, the existence of another DNA-binding protein of the IRF family that can function as a regulatory component in infected or IFN-treated cells could provide further complexity and specificity to the regulatory network mediating the responses to viral infection.
